Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from a phase 3 trial of gefurulimab, a once-weekly self-administered treatment ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈